Pipeline

Cryopreserved Platelets (CLPH-511) – Cellphire’s leading technology (CLPH-511) - have been developed in response to the acknowledgement that hemorrhage continues to be a leading cause of mortality, that platelets have been shown to mitigate this burden and the fact that room-temperature stored platelets are frequently in short supply, expired or unavailable.
These challenges exist from the limited supply and short shelf life of LSPs (5-7 days) resulting in an inability to stockpile platelets, thus leading to potential platelet shortages.
This means CLPH-511 has the potential to become an alternative to room temperature stored platelets for acute hemorrhage. Unlike any other platelet therapy, its unique long shelf life means it can address shortages, it can be stockpiled and thereby eliminate “platelet deserts” and change the current platelet landscape.  
FPH (freeze-dried platelet hemostat) is a highly differentiated technology platform with significant potential to address unmet needs in disorders of hemostasis, vascular permeability, inflammation and fibrosis. CLPH-211 has advanced to the clinic in a variety of hemorrhage indications, while CLPH-251 (acute TBI and ICH) is pre-IND stage.

Cellphire has been successful in loading and stabilizing different types of biologic molecules into platelets. CLPH-701 is a platform technology, currently in discovery phase.

To learn more about the thinking behind our science, click here.